Secondary chemotherapy of advanced breast cancer

A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1973-03, Vol.31 (3), p.660-663
Main Authors: Goldenberg, Ira S., McMahan, C. A., Escher, George C., Volk, Herbert, Ansfield, Fred J., Olson, Kenneth B.
Format: Article
Language:English
Subjects:
Adult
Aged
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Chlorambucil - administration & dosage
Chlorambucil - therapeutic use
Female
Humans
Hydrocortisone - administration & dosage
Hydrocortisone - therapeutic use
Middle Aged
Neoplasm Metastasis
Prednisone - administration & dosage
Prednisone - therapeutic use
Remission, Spontaneous
Triiodothyronine - administration & dosage
Triiodothyronine - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4606-923aa430afe9ed52576585d94df46488a3c693f289e8dad8693703657374402d3
container_end_page 663
container_issue 3
container_start_page 660
container_title Cancer
container_volume 31
creator Goldenberg, Ira S.
McMahan, C. A.
Escher, George C.
Volk, Herbert
Ansfield, Fred J.
Olson, Kenneth B.
description A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11.8% for hydrocortisone with triiodothyronine, and 9.8% for chlorambucil alone were defined. For the patient with advancing metastatic disease who has received initial hormonal therapy, it is recommended that further treatment with the combination of chlorambucil and prednisone be considered.
doi_str_mv 10.1002/1097-0142(197303)31:3<660::AID-CNCR2820310326>3.0.CO;2-U
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81861899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81861899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4606-923aa430afe9ed52576585d94df46488a3c693f289e8dad8693703657374402d3</originalsourceid><addsrcrecordid>eNqVkE9rGzEQxUVJSd0kH6Gwp5Ac1h1pJK3khNCwzT8INTQ15DYokpY42F5nZbf421fGJpAcAjkNjzfzZubH2A8OfQ4gvnOwVQlciiNuKwQ8Rj7AU61hMDi_-VnWv-rfwghADij0GfahXw9PRDn6xHovozusBwCmVBLvv7CvKT1lWQmFu2xXaovKqh6Du-jbWXDdqvCPcdouHmPn5quibQoX_rqZj6F46KJLi8KvVbfPPjdukuLBtu6x0eXFn_q6vB1e3dTnt6WXGnRpBTonEVwTbQxKqEoro4KVoZFaGuPQ5xMaYWw0wQWTRQWoVYWVlCAC7rHDTe68a5-XMS1oOk4-TiZuFttlIsON5sba3Hi_afRdm1IXG5p342l-iDjQGiatidCaCG1gEnJCyjCJMkx6DTM7QPWQBI1y9LftDcuHaQwvwVt62fcb_994Elcf2Pvu2jcO_geYzo69</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81861899</pqid></control><display><type>article</type><title>Secondary chemotherapy of advanced breast cancer</title><source>EZB Electronic Journals Library</source><creator>Goldenberg, Ira S. ; McMahan, C. A. ; Escher, George C. ; Volk, Herbert ; Ansfield, Fred J. ; Olson, Kenneth B.</creator><creatorcontrib>Goldenberg, Ira S. ; McMahan, C. A. ; Escher, George C. ; Volk, Herbert ; Ansfield, Fred J. ; Olson, Kenneth B.</creatorcontrib><description>A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11.8% for hydrocortisone with triiodothyronine, and 9.8% for chlorambucil alone were defined. For the patient with advancing metastatic disease who has received initial hormonal therapy, it is recommended that further treatment with the combination of chlorambucil and prednisone be considered.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(197303)31:3&lt;660::AID-CNCR2820310326&gt;3.0.CO;2-U</identifier><identifier>PMID: 4693595</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Chlorambucil - administration &amp; dosage ; Chlorambucil - therapeutic use ; Female ; Humans ; Hydrocortisone - administration &amp; dosage ; Hydrocortisone - therapeutic use ; Middle Aged ; Neoplasm Metastasis ; Prednisone - administration &amp; dosage ; Prednisone - therapeutic use ; Remission, Spontaneous ; Triiodothyronine - administration &amp; dosage ; Triiodothyronine - therapeutic use</subject><ispartof>Cancer, 1973-03, Vol.31 (3), p.660-663</ispartof><rights>Copyright © 1973 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4606-923aa430afe9ed52576585d94df46488a3c693f289e8dad8693703657374402d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4693595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldenberg, Ira S.</creatorcontrib><creatorcontrib>McMahan, C. A.</creatorcontrib><creatorcontrib>Escher, George C.</creatorcontrib><creatorcontrib>Volk, Herbert</creatorcontrib><creatorcontrib>Ansfield, Fred J.</creatorcontrib><creatorcontrib>Olson, Kenneth B.</creatorcontrib><title>Secondary chemotherapy of advanced breast cancer</title><title>Cancer</title><addtitle>Cancer</addtitle><description>A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11.8% for hydrocortisone with triiodothyronine, and 9.8% for chlorambucil alone were defined. For the patient with advancing metastatic disease who has received initial hormonal therapy, it is recommended that further treatment with the combination of chlorambucil and prednisone be considered.</description><subject>Adult</subject><subject>Aged</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Chlorambucil - administration &amp; dosage</subject><subject>Chlorambucil - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocortisone - administration &amp; dosage</subject><subject>Hydrocortisone - therapeutic use</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Prednisone - administration &amp; dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Remission, Spontaneous</subject><subject>Triiodothyronine - administration &amp; dosage</subject><subject>Triiodothyronine - therapeutic use</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1973</creationdate><recordtype>article</recordtype><recordid>eNqVkE9rGzEQxUVJSd0kH6Gwp5Ac1h1pJK3khNCwzT8INTQ15DYokpY42F5nZbf421fGJpAcAjkNjzfzZubH2A8OfQ4gvnOwVQlciiNuKwQ8Rj7AU61hMDi_-VnWv-rfwghADij0GfahXw9PRDn6xHovozusBwCmVBLvv7CvKT1lWQmFu2xXaovKqh6Du-jbWXDdqvCPcdouHmPn5quibQoX_rqZj6F46KJLi8KvVbfPPjdukuLBtu6x0eXFn_q6vB1e3dTnt6WXGnRpBTonEVwTbQxKqEoro4KVoZFaGuPQ5xMaYWw0wQWTRQWoVYWVlCAC7rHDTe68a5-XMS1oOk4-TiZuFttlIsON5sba3Hi_afRdm1IXG5p342l-iDjQGiatidCaCG1gEnJCyjCJMkx6DTM7QPWQBI1y9LftDcuHaQwvwVt62fcb_994Elcf2Pvu2jcO_geYzo69</recordid><startdate>197303</startdate><enddate>197303</enddate><creator>Goldenberg, Ira S.</creator><creator>McMahan, C. A.</creator><creator>Escher, George C.</creator><creator>Volk, Herbert</creator><creator>Ansfield, Fred J.</creator><creator>Olson, Kenneth B.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197303</creationdate><title>Secondary chemotherapy of advanced breast cancer</title><author>Goldenberg, Ira S. ; McMahan, C. A. ; Escher, George C. ; Volk, Herbert ; Ansfield, Fred J. ; Olson, Kenneth B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4606-923aa430afe9ed52576585d94df46488a3c693f289e8dad8693703657374402d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1973</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Chlorambucil - administration &amp; dosage</topic><topic>Chlorambucil - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocortisone - administration &amp; dosage</topic><topic>Hydrocortisone - therapeutic use</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Prednisone - administration &amp; dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Remission, Spontaneous</topic><topic>Triiodothyronine - administration &amp; dosage</topic><topic>Triiodothyronine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldenberg, Ira S.</creatorcontrib><creatorcontrib>McMahan, C. A.</creatorcontrib><creatorcontrib>Escher, George C.</creatorcontrib><creatorcontrib>Volk, Herbert</creatorcontrib><creatorcontrib>Ansfield, Fred J.</creatorcontrib><creatorcontrib>Olson, Kenneth B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldenberg, Ira S.</au><au>McMahan, C. A.</au><au>Escher, George C.</au><au>Volk, Herbert</au><au>Ansfield, Fred J.</au><au>Olson, Kenneth B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Secondary chemotherapy of advanced breast cancer</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1973-03</date><risdate>1973</risdate><volume>31</volume><issue>3</issue><spage>660</spage><epage>663</epage><pages>660-663</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11.8% for hydrocortisone with triiodothyronine, and 9.8% for chlorambucil alone were defined. For the patient with advancing metastatic disease who has received initial hormonal therapy, it is recommended that further treatment with the combination of chlorambucil and prednisone be considered.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>4693595</pmid><doi>10.1002/1097-0142(197303)31:3&lt;660::AID-CNCR2820310326&gt;3.0.CO;2-U</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1973-03, Vol.31 (3), p.660-663
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_81861899
source EZB Electronic Journals Library
subjects Adult
Aged
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Chlorambucil - administration & dosage
Chlorambucil - therapeutic use
Female
Humans
Hydrocortisone - administration & dosage
Hydrocortisone - therapeutic use
Middle Aged
Neoplasm Metastasis
Prednisone - administration & dosage
Prednisone - therapeutic use
Remission, Spontaneous
Triiodothyronine - administration & dosage
Triiodothyronine - therapeutic use
title Secondary chemotherapy of advanced breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A55%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Secondary%20chemotherapy%20of%20advanced%20breast%20cancer&rft.jtitle=Cancer&rft.au=Goldenberg,%20Ira%20S.&rft.date=1973-03&rft.volume=31&rft.issue=3&rft.spage=660&rft.epage=663&rft.pages=660-663&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(197303)31:3%3C660::AID-CNCR2820310326%3E3.0.CO;2-U&rft_dat=%3Cproquest_cross%3E81861899%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4606-923aa430afe9ed52576585d94df46488a3c693f289e8dad8693703657374402d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=81861899&rft_id=info:pmid/4693595&rfr_iscdi=true